Do pharmaceutical score cards give us the answers we seek?

New Zealand Medical Journal

Volumn 124, Issue 1346, 2011, Pages 69-74

  Moodie, Peter ^a   Metcalfe, Scott ^b   Poynton, Matthew ^b  

^a Pharmaceutical Management Agency ^*

^b Pharmaceutical Management Agency   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ETIRACETAM; HIRULOG; PIOGLITAZONE; ROSIGLITAZONE; DRUG;

ANTICOAGULATION; ARTICLE; AUSTRALIA; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; EPILEPSY; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; NEW ZEALAND; PHARMACY; SCORING SYSTEM; UNITED STATES; DRUG APPROVAL; ECONOMICS; FEMALE; HEALTH CARE DELIVERY; HEALTH INSURANCE; MALE; NOTE; PRESCRIPTION;

DRUG APPROVAL; DRUG PRESCRIPTIONS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; PHARMACEUTICAL PREPARATIONS;

EID: 84855853898     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rawlins MD, Chalkidou K. The opportunity cost of cancer care: a statement from NICE. Lancet Oncol. 2011;12:931-2. http://www.sciencedirect.com/science/article/pii/S1470204511702182
2. Braae R, McNee W, Moore D. Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience. Pharmacoeconomics 1999;16:649-60. http://adisonline.com/pharmacoeconomics/Citation/1999/16060/Managing_Pharmaceutical_E xpenditure_while.4.aspx
3. Cumming J, Mays N, Daubé J. How New Zealand has contained expenditure on drugs. BMJ. 2010 May 18;340:c2441. http://www.bmj.com/content/340/bmj.c2441.full
4. Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust. 2008;188:26-8. http://www.mja.com.au/public/issues/188_01_070108/raf10125_fm.html
5. Grocott R, Metcalfe S. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. N Z Med J. 2005;118:U1690. http://journal.nzma.org.nz/journal/118-1223/1690/
6. Grocott R. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience. Exp Rev Pharmacoecon 2009;9:181-7. http://www.expert-reviews.com/doi/abs/10.1586/erp.09.2
7. PHARMAC. Access to medicines in Australia and New Zealand: a high level Comparison. PHARMAC Working Paper, March 2010 (draft) (comparison as at August 2009).
8. Wonder M, Milne R. Access to new medicines in New Zealand and Australia. N Z Med J. 2011;124(1346). http://journal.nzma.org.nz/journal/124-1346/4966
9. Coombes R. Cancer drugs: swallowing big pharma's line? BMJ. 2007;334:1034-5. http://www.bmj.com/content/334/7602/1034.full
10. Coleman MP. Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1 75). Ann Oncol. 2007;18:1433-5. http://annonc.oxfordjournals.org/content/18/9/1433.long
11. Brougham M, Metcalfe S, McNee W. Our advice? Get a budget! Healthcare Papers 2002;3:83-5. http://www.longwoods.com/product.php?productid=16915
12. Metcalfe S, Grocott R. Health economic assessment: New Zealand in fact has no costeffectiveness threshold. IJERPH 2010;7:1831-1834. http://www.mdpi.com/1660-4601/7/4/1831/pdf
13. Crausaz S, Metcalfe S. PHARMAC's response on gemcitabine and transparency. N Z Med J. 2005;118:U1741. http://journal.nzma.org.nz/journal/118-1225/1741/
14. Moodie P, McNee W, Metcalfe S. PHARMAC welcomes debate. N Z Med J. 2005;118:U1572. http://journal.nzma.org.nz/journal/118-1218/1572/
15. Annual Report of Pharmaceutical Management Agency (PHARMAC) for the year ended 30 June 2010. Presented to the House of Representatives pursuant to section 150(3) of the Crown Entities Act 2004. http://www.pharmac.govt.nz/2010/10/22/2010%20Annual%20Report.pdf
16. PHARMAC. Funding options that PHARMAC had before it during 2009/10 that were not funded (implemented) during that year. http://www.pharmac.govt.nz/2010/10/22/Unfunded%20proposals.pdf
17. Annual Report of Pharmaceutical Management Agency (PHARMAC) for the year ended 30 June 2011. Presented to the House of Representatives pursuant to section 150(3) of the Crown Entities Act 2004. http://www.pharmac.govt.nz/2011/10/19/10.11%20Annual%20Report.pdf
18. Morgan S, Boothe K. Prescription drug subsidies in Australia and New Zealand. Aust Prescr 2010;33:2-4. http://www.australianprescriber.com/magazine/33/1/2/4
19. Spinks JM, Richardson JR. Paying the right price for pharmaceuticals: a case study of why the comparator matters. Aust Health Rev. 2011;35:267-72. http://www.publish.csiro.au/index.cfm?paper=AH10930